7.7
[1]. Obaseki AO, Coker HB. The anticoagulant activity of some selected warfarin analogues. J Pharm Pharmacol. 197 Feb;39():1-.
[]. A E Rettie, et al. Impaired (S)-warfarin metabolism catalysed by the R1C allelic variant of CYPC9. Pharmacogenetics. 199 Feb;(1):39-.
[3]. Drew R Jones, et al. Hydroxywarfarin metabolites potently inhibit CYPC9 metabolism of S-warfarin. Chem Res Toxicol. 010 May 17;3():939-.
[]. Erik L Regalado, et al. Investigation of two-dimensional high performance liquid chromatography approaches for reversed phase resolution of warfarin and hydroxywarfarin isomers. J Chromatogr A. 01 Oct 10:1363:00-6.
[]. Grover P Miller, et al. Identification of hydroxywarfarin binding site in human UDP glucuronosyltransferase 1a10: phenylalanine90 is crucial for the glucuronidation of 6- and 7-hydroxywarfarin but not -hydroxywarfarin. Drug Metab Dispos. 00 Nov;36(11):11-.
H30-H31
P6-P70-P0-P330-P01
GHS0,GHS07
361